|
|
|
| Comparison of Efficacy of Teguio and Apatinib in the Treatment of Advanced Refractory Ovarian Cancer and the Effect of Drugs on HE4 CA125 and CA199 |
| LIU Jianting, ZHANG Rongsheng, DENG Tianli, et al |
| The First Affiliated Hospital of Dali University, Yunnan Dali 671000, China |
|
|
|
|
Abstract Objective: To observe the clinical efficacy of apatinib and tigio for patients with advanced refractory ovarian cancer (OC),and to explore the effect of the above drugs on human epididymal secretory protein 4(HE4),carbohydrate antigen 125(CA125) and carbohydrate antigen 199(CA199). Methods: Retrospective analysis was conducted of 88 patients with refractory OC from April 2018 to September 2019(TNM Ⅲ-Ⅳ),who were divided into observation group (treated with apatinib mesylate) and control group (treated with tigio),with 44 cases in each. The changes of HE4,CA125 and CA199 were compared between the two groups. The total effective rates,disease control rates and adverse reactions were compared between the two groups. Results: After treatment,the total effective rate of observation group was 50.00%,which was significantly higher than that of control group (P<0.05). The serum HE4,CA125,CA199 levels in the observation group decreased significantly compared with those in the control group (all P<0.05). The rates of non-hematological and hematological adverse reactions were 75.00% and 77.27% in the control group after treatment; there was a significant increase in 52.27% and 36.36% of the observation group (all P<0.05). Conclusion: Apatinib treatment for advanced refractory OC patients is ideal,with less adverse reactions and better disease control. It is considered to be related to the obvious inhibition of apatinib HE4、CA125、CA199 level,which has clinical value.
|
|
|
|
|
|
[1] 段文丽,张燕,张琼,等.CIK联合TP方案治疗复发性卵巢癌的临床疗效观察[J].重庆医学,2019,48(8):69~72.
[2] 李春碧,伏攀,袁慧.子宫内膜癌患者血清肿瘤标志物HE4,CA125,CA199的临床应用价值[J].实用癌症杂志,2019,34(9):1412~1413.
[3] 马爱矿,高华丽,王敏,等.HE4、CA125和CA199联合D-二聚体检测在卵巢癌早期诊断中的应用[J].中国肿瘤临床与康复,2019,26(7):793~795.
[4] 刘东雷,吴恺,吉浩哲,等.血清肿瘤标志物水平及美国东部肿瘤协作组评分在评估非小细胞肺癌根治手术后的预后价值[J].中华实验外科杂志,2019,36(10):1896~1896.
[5] 漆仲春,张涛,高辉,等.甲磺酸阿帕替尼片用于标准治疗失败后卵巢癌治疗的有效性和安全性[J].现代肿瘤医学,2019,27(12):138~141.
[6] 王珏,杜琰,王烨菁,等.2002年至2011年上海市原卢湾区居民卵巢癌的发病和死亡资料分析[J].中国癌症杂志,2018,28(6):12~15.
[7] 宋佳伟,徐珊珊,陈慧娟,等.阿帕替尼致手足综合征及3级高血压的药学监护1例[J].中国新药与临床杂志,2018,37(4):247~248.
[8] 成远,耿海云,华海清.阿帕替尼联合拓扑替康多线治疗铂类耐药复发性卵巢癌2例报告[J].肿瘤防治研究,2018,45(3):188~190.
[9] 王春阳,王羽,王子龙.血清HE4TK1CA199联合检测对卵巢癌的诊断价值[J].河北医学,2019,25(7):1081~1085.
[10] 李丹妍,王銮虹,邱小华,等.血清CA125、CA199、AFP和CEA联合检测在卵巢癌诊断中的临床价值[J].中国妇幼保健,2018,33(8):1731~1733.
[11] 毛爱芹,张育荣,李宝奇,等.CA19-9、CA72-4和CEA在阿帕替尼治疗胃癌患者中的变化及意义[J].标记免疫分析与临床,2018,25(5):657~660.
[12] 王丽丽,李鑫,侯定坤,等.阿帕替尼治疗6例晚期难治性卵巢癌的临床观察[J].中国肿瘤临床,2018,45(7):44~47. |
|
|
|
2021, Vol. 27 
